SOPHiA GENETICS SA Ordinary Shares (SOPH) is a publicly traded Healthcare sector company. As of October 20, 2026, SOPH trades at $6.46 with a market cap of $572.91M and a P/E ratio of 0.00. SOPH moved +0.00% today. Year to date, SOPH is +38.97%; over the trailing twelve months it is +50.58%. Its 52-week range spans $2.58 to $8.98. Analyst consensus is strong buy with an average price target of $10.00. Rallies surfaces SOPH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
SOPHiA Genetics, Myriad team up to advance prostate cancer genomic instability score technology: SOPHiA Genetics and Myriad are collaborating to develop a prostate cancer genomic instability score for AstraZeneca precision oncology trials. Myriad’s MyChoice CDx test will generate the score, and SOPHiA Genetics plans to integrate it into its Extended Homologous Recombination Solution.
| Metric | Value |
|---|---|
| Price | $6.46 |
| Market Cap | $572.91M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $8.98 |
| 52-Week Low | $2.58 |
| Volume | 7.29K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
5 analysts cover SOPH: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $10.00.